Thera-SAbDab

CAPLACIZUMAB

>   Structural Summary
TherapeuticCaplacizumab
TargetVWF
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAAGVRAEDGRVRTLPSEYTFWGQGTQVTVSS
Light Chainna
100% seqID Fv Structure7a6o [Fvs: B], 7eow [Fvs: B]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatNanobody
Isotypena
Highest Clinical Trial (October '21)Approved
Estimated Status (October '21)NFD
Recorded Developmental TechnologyNanobody Technology
INN Year Proposed2011
INN Year Recommended2012
Companies InvolvedAblynx
Conditions ApprovedThrombotic thrombocytopenic purpura
Conditions Activena
Conditions DiscontinuedThrombosis
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy